Company · CIK 1806540

# Lycia Therapeutics, Inc.

| CIK | [1806540](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001806540) (SEC EDGAR) |
| --- | --- |
| Industry (SIC) | 2836 — Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
| Business address | CA |
| Listed | LYCA (Nasdaq) |
| First annual or quarterly report | none on EDGAR |

## Offerings

 1 registration

| Registration | Label and status | First filed | Last event | Filings |
| --- | --- | --- | --- | --- |
| 333-299300 | IPO Final prospectus | 2026-10-05 | 2026-10-23 | 4 |

## Filings

 5

| Filed | Filing | Registration | Accession |
| --- | --- | --- | --- |
| 2026-10-23 | [424B4](https://www.sec.gov/Archives/edgar/data/1806540/000162828026067048/0001628280-26-067048-index.htm) Final prospectus | 333-299300 | 0001628280-26-067048 |
| 2026-10-22 | [EFFECT](https://www.sec.gov/Archives/edgar/data/1806540/999999999526003321/9999999995-26-003321-index.htm) Declared effective | 333-299300 | 9999999995-26-003321 |
| 2026-10-20 | [S-1/A](https://www.sec.gov/Archives/edgar/data/1806540/000162828026066381/0001628280-26-066381-index.htm) Amendment | 333-299300 | 0001628280-26-066381 |
| 2026-10-05 | [S-1](https://www.sec.gov/Archives/edgar/data/1806540/000162828026064973/0001628280-26-064973-index.htm) Registration filed | 333-299300 | 0001628280-26-064973 |
| 2026-07-02 | [DRS](https://www.sec.gov/Archives/edgar/data/1806540/000162827926000815/0001628279-26-000815-index.htm) Draft made public | 377-09537 | 0001628279-26-000815 |

[All filings of this company](https://equitycapital.markets/filings?cik=1806540) · [CSV](https://equitycapital.markets/filings.csv?cik=1806540)

---
Source page: https://equitycapital.markets/company/1806540 · Data: U.S. SEC EDGAR · CC BY 4.0